Abstract

ObjectivesBimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
E067 Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drugnaïve patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, activereference study
William R Tillett ... Yoshiya Tanaka
Rheumatology (Oxford, England) | VOL. 63
William R Tillett, et. al.William R Tillett ... Yoshiya Tanaka
24 Apr 2024
POS1534 BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDY
W Tillett ... R Bajracharya
Annals of the Rheumatic Diseases | VOL. 82
W Tillett, et. al.W Tillett ... R Bajracharya
30 May 2023
POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
L Coates ... A Asahina
Annals of the Rheumatic Diseases | VOL. 82
L Coates, et. al.L Coates ... A Asahina
30 May 2023
P274 The effect of ixekizumab versus adalimumab on individual components of the ACR composite score, with and without concomitant methotrexate or other conventional synthetic DMARDs, at 52 weeks in patients with psoriatic arthritis
Allan Kiprianos ... Luca Idolazzi
Rheumatology (Oxford, England) | VOL. 61
Allan Kiprianos, et. al.Allan Kiprianos ... Luca Idolazzi
23 Apr 2022
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Mutilating arthropathy with skin nodules.
Tsz On Lam ... Lai-Shan Tam
Annals of the rheumatic diseases | VOL. -
Tsz On Lam, et. al.Tsz On Lam ... Lai-Shan Tam
08 Aug 2024
From fibrositis to fibromyalgia to nociplastic pain: how rheumatology helped get us here and where do we go from here?
Daniel J Clauw
Annals of the Rheumatic Diseases | VOL. -
Daniel J ClauwDaniel J Clauw
06 Aug 2024
Development of international consensus on a standardised image acquisition protocol for diagnostic evaluation of the sacroiliac joints by MRI: an ASAS–SPARTAN collaboration
Robert G W Lambert ... Walter P Maksymowych
Annals of the Rheumatic Diseases | VOL. -
Robert G W Lambert, et. al.Robert G W Lambert ... Walter P Maksymowych
06 Aug 2024
Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases
Ann-Kathrin Eiers ... Jan P Tuckermann
Annals of the Rheumatic Diseases | VOL. -
Ann-Kathrin Eiers, et. al.Ann-Kathrin Eiers ... Jan P Tuckermann
06 Aug 2024
View more papers